Prof Dr. Maxime CULOT - Alternative toxicology - Best Researcher Award 

University of Artois - France

Author Profile

• Scopus
• Orcid

Early Academic Pursuits

Prof Dr. Maxime Culot began his academic journey at the University of Artois, where he obtained his Bachelor's and Master's degrees in Life Sciences and Cell Biology & Physiology, respectively. His passion for neuroscience led him to pursue a Master's degree in Biology at the University of Lille Nord de France. This diverse educational background provided him with a solid foundation in biological sciences, preparing him for his future research endeavors.

In 2004, Culot embarked on his doctoral studies at the University of Artois, focusing on Neurosciences. This marked the beginning of his deep dive into understanding the intricacies of the brain and its barriers, laying the groundwork for his subsequent contributions to the field.

Professional Endeavors

Following the completion of his Ph.D., Culot ventured into academia as a Lecturer at the University of Artois, where he shared his expertise with aspiring scientists. His academic journey then took him to Ghent University as a Postdoctoral Fellow, broadening his horizons and fostering collaborations beyond his home institution.

Culot's postdoctoral experiences extended to industry as he joined Medimmune, Cambridge UK, supported by AstraZeneca, Sweden. This industry exposure provided him with valuable insights into pharmaceutical research and drug development, enriching his academic perspective.

Upon his return to academia, Culot assumed the role of Associate Professor at the BBB Laboratory (UR 2465), University of Artois. Over the years, he steadily rose through the ranks, culminating in his appointment as a Full Professor in September 2023. Throughout his academic career, Culot demonstrated a relentless commitment to advancing scientific knowledge in the field of neurobiology and drug delivery.

Contributions and Research Focus

Prof Dr. Culot's research primarily revolves around the use of in vitro models in ADME (Absorption, Distribution, Metabolism, and Excretion) studies, with a particular emphasis on the blood-brain barrier (BBB). He has leveraged various in vitro BBB models, including those derived from animal sources and human stem cells, to investigate the transport of xenobiotics across biological barriers.

His laboratory's repertoire also encompasses intestinal and neuronal in vitro models, reflecting a multidisciplinary approach to understanding drug pharmacokinetics and toxicology. Through his collaborative efforts, Culot has contributed significantly to unraveling the complexities of drug permeability and toxicity, paving the way for safer and more effective therapeutic interventions.

Accolades and Recognition

Prof Dr. Culot's outstanding contributions to the field have been recognized through numerous awards and accolades. Notably, he received the International Brain Barriers Society's award in 2011, underscoring his pioneering work in barrier biology. Additionally, his prolific publication record and leadership roles in prestigious academic journals attest to his stature as a respected figure in the scientific community.

Impact and Influence

Prof Dr. Culot's impact extends beyond the confines of his laboratory, as evidenced by his involvement in various EU-funded projects and private research contracts with pharmaceutical companies. His research findings have direct implications for drug development and safety assessment, thereby influencing clinical practice and regulatory guidelines.

Furthermore, Culot's mentorship of junior researchers and supervision of doctoral theses have nurtured the next generation of scientists, ensuring continuity in scientific innovation and discovery. His collaborative ethos and dedication to scientific excellence have fostered a culture of interdisciplinary research, fostering fruitful collaborations both within academia and industry.

Legacy and Future Contributions

As Maxime Culot continues to spearhead cutting-edge research at the University of Artois, his legacy as a trailblazer in neuropharmacology and in vitro modeling is firmly established. Looking ahead, he remains committed to pushing the boundaries of knowledge in ADME research, with a focus on harnessing emerging

Notable Publication

• Enhancing Oral Delivery of Biologics: A Non-Competitive and Cross-Reactive Anti-Leptin Receptor Nanofitin Demonstrates a Gut-Crossing Capacity in an Ex Vivo Porcine Intestinal Model Pharmaceutics 2024-01-16.
• Challenges and Opportunities in the Oral Delivery of Recombinant Biologics Pharmaceutics 2023-05-05.
• Challenges and opportunities in the use of transcriptomics characterization for human iPSC-derived BBB models Toxicology in Vitro 2022.
• An in vitro strategy using multiple human induced pluripotent stem cell-derived models to assess the toxicity of chemicals: A case study on paraquat Toxicology in Vitro 2022-06.
• Application of in vitro data in physiologically-based kinetic models for quantitative in vitro-in vivo extrapolation: A case-study for baclofen Toxicology in Vitro 2021.